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Background: Neutrophil elastase (NE)-mediated inﬂammation contributes to lung damage in cystic ﬁbrosis (CF). We investigated if DX-890, a
small-protein NE inhibitor, could reduce neutrophil trans-epithelial migration and reduce activity released from neutrophils and NE-induced
cytokine expression in airway epithelial cells.
Methods: Activated blood neutrophils (CF and healthy) treated ±DX-890 were assayed for NE activity. Transmigration of calcein-labeled neutro-
phils was studied using a 16HBE14o− epithelial monolayer. IL-8 release from primary nasal epithelial monolayers (CF and healthy) was measured
after treatment ±DX-890 and NE or CF sputum.
Results: DX-890 reduced NE activity from neutrophils (CF and healthy) and reduced neutrophil transmigration. DX-890 pre-treatment reduced
IL-8 release from epithelial cells of healthy or CF subjects after stimulation with NE and CF sputum sol. All improvements with DX-890 were
statistically signiﬁcant (pb0.05).
Conclusions: DX-890 reduces NE-mediated transmigration and inﬂammation. NE inhibition could be useful in managing neutrophilic airway
inﬂammation in CF.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Epithelial; Protease; Airway1. Introduction
Persistent neutrophil influx to the airway is a feature of
cystic fibrosis. Failure of the macrophage clearing system for
apoptotic cells leads to neutrophil death by secondary necrosis
and the release of high levels of pro-inflammatory mediators
including the proteolytic enzyme neutrophil elastase (NE) [1]
and oxidants which inactivate the anti-proteases α1-antitrypsin1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
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E-mail address: m.ennis@qub.ac.uk (M. Ennis).and secretory leukoprotease inhibitor which normally inacti-
vates extracellular NE, thus protecting the airway [2].
Extracellular NE degrades many components of the extracel-
lular matrix including elastin, collagen types I-IV, proteoglycan
and fibronectin [3] as well as complement factors and their re-
ceptors [4], immunoglobulins [5] and surfactant proteins [6],
further compromising the immune defense. NE perpetuates
inflammation by stimulating airway epithelial cells to release
pro-inflammatory mediators such as the chemokine IL-8
[7–10]. NE also induces goblet cells and submucosal glands
to secrete mucin proteins [11] and impairs the ability of macro-
phages to recognize and phagocytose apoptotic neutrophils
[12].
Inhibition of NE may reduce CF airway inflammation but, to
date, no NE inhibitors have been licensed for use in treating
airway inflammation in CF. A comprehensive review ofby Elsevier B.V. All rights reserved.
Table 1
Characteristics of volunteers in the nasal epithelial cell study.
Cystic ﬁbrosis (n=10) Healthy (n=7)
Male (%) 50.0 57.1
Age (years) 22 (22,25) 28 (23.5, 31.5)
BMI (kg/m2) 21.5 (18.9, 22) 20.3 (20.1, 21)
FEV1
* (% predicted) 65 (55, 74) –
FVC* (L) 3.04 (2.51, 4.03) –
All data were median and interquartile range apart from the percentage of males
(median only). Lung function testing was not performed for healthy partici-
pants. BMI: body mass index, FEV1: forced expiratory flow in one second,
FVC: forced vital capacity.
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found elsewhere [13].
DX-890 (Dyax Corp., USA) is a potent and selective small-
protein inhibitor of NE which was discovered by phage display
[14]. This study investigated if DX-890 could reduce NE
activity from activated neutrophils and IL-8 secretion from air-
way epithelial cells, and if DX-890 could reduce neutrophil
trans-epithelial migration.
2. Methods
All materials were from Sigma Aldrich unless stated other-
wise. This study was approved by the Office for Research
Ethics Committees Northern Ireland (ORECNI) and all
participants gave written informed consent.
2.1. Neutrophil isolation
Neutrophils were isolated from heparinized venous blood of
volunteers by a dual density centrifugation method using
Histopaque-1077 and Histopaque-1119 according to the manu-
facturer's instructions (Sigma Aldrich). In all experiments
neutrophil samples were N98% viable as determined by Trypan
blue staining. Blood was either from clinically stable F508del
homozygous CF patients attending outpatient clinics in Belfast
City Hospital, or from healthy volunteers.
2.2. Neutrophil elastase activity from activated neutrophils
Neutrophils (1.25×104 cells) were primed by pre-incubation
with cytochalasin b (5 μg/ml) ±DX-890 (10 nm–1 μM) for
10 minutes at 37 °C. Neutrophils were then stimulated with
fMLP (100 nM) for a further 10 minutes before addition of the
colorimetric substrate N-methoxysuccinyl-Ala-Ala-Pro-Val-
pNA (100 ng/ml; Elastin Products). Cleavage of substrate was
immediately monitored colorimetrically at 405 nm every
45 seconds for 10 minutes. Each reaction (200 μl) was
performed in triplicate in a 96-well plate. Initial reaction rates
are reported as the change in absorbance per minute.
2.3. Neutrophil transmigration
2.3.1. Production of the epithelial monolayer
16HBE14o− cells (1×106 cells/ml) were seeded in the
apical chambers of collagen coated Transwells (Corning
Costar). Cells were fed every second day with minimal essen-
tial media (MEM; Invitrogen) with 10% (v/v) fetal bovine
serum (FBS) and 1% (v/v) penicillin/streptomycin (250 μl api-
cal, 600 μl basolateral) until transepithelial electrical resistance
(TEER), measured every second day, stopped rising linearly,
indicating a confluent, polarized monolayer.
2.3.2. Calcein labeling of neutrophils
Blood neutrophils from healthy volunteers were fluorescent-
ly labeled by incubation with 1.5 μM calcein-AM for
20 minutes in the dark at 37 °C, followed by two PBS washes
and centrifugation (200g, 10 minutes, room temperature).Cells were kept in darkness during and after the labeling proce-
dure to avoid photocytotoxocity associated with calcein-AM.2.3.3. Neutrophil transmigration
Culture media was washed from the epithelial monolayer
with HBSS (Gibco) and 600 μl fMLP (100 nM in HBSS) was
added to the basolateral compartment. Aliquots of calcein-
labeled neutrophils (1×106 cells/ml; 200 μl) were pre-
incubated ±DX-890 (500 nM) at 37 °C for 10 minutes, then
added to the apical chamber of Transwells and the plate was in-
cubated at 37 °C for 2 hours. Following incubation, liquid in
the apical chamber was aspirated, and the upper compartments
were washed with HBSS to remove any neutrophils that had
not transmigrated through the monolayer to the basolateral
side of the membrane. Fluorescence was measured using a
bottom-reading probe and an area scan of the entire well. Exci-
tation and emission wavelengths were 495 nm and 520 nm
respectively.2.4. Preparation of the soluble fraction of CF sputum
Spontaneously expectorated sputum samples were collected
from CF inpatients in the adult CF ward in Belfast City Hospi-
tal. Samples were processed using PBS as described by Nixon
et al. [15]. Sputum sol from seven patients was pooled before
being used to stimulate airway epithelial cells.2.5. Nasal epithelial cell culture
Nasal epithelial cells (NEC) were obtained by nasal brush-
ing from CF (F508del homozygous) and healthy volunteers as
previously described [16]. Participant characteristics are de-
scribed in Table 1. Cells (passage 2-4; 1.5×105 cells/ml)
were seeded in a collagen coated 24-well plate. The next day,
cells were approximately 80% confluent and were pre-treated
with DX-890 (200–500 nM) for 30 minutes, then stimulated
with NE 50 nM or CF sputum sol 1:100 for 4 hours. Culture
media was replaced and cells were incubated for 24 hours.
Cell-free supernatant was stored at −20° for future IL-8 mea-
surement using the DuoSet IL-8 ELISA kit (R&D Systems)
according to the manufacturer's instructions.
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Data are non-parametric and are therefore presented as me-
dian± interquartile range. Comparisons within groups were
made using Wilcoxon signed rank test or the Kruskal–Wallis
test. Comparisons between groups (i.e. between CF and non-
CF groups) were made using the Mann–Whitney U test. A p
value ≤0.05 was considered significant.
3. Results
3.1. Inhibition of NE activity in neutrophils
NE activity in non-stimulated neutrophils was similar be-
tween healthy and CF neutrophils. fMLP-induced NE release
was higher from healthy neutrophils than from CF neutrophils
(p=0.025). Pre-treatment of neutrophils with DX-890 reduced
activity of NE released after fMLP stimulation. DX-890
10 nM partially reduced NE activity but DX-890 100 nM and
1 μM reduced NE activity to below the level of spontaneous re-
lease in both healthy and CF neutrophils (Fig. 1).
3.2. Neutrophil transmigration
TEER values of 16HBE14o− monolayers increased over
time and reached a maximum of 0.6 ohms/cm2 after
7–15 days, indicating confluence (data not shown).
Median (range) spontaneous neutrophil transmigration was
25.2% (22.2, 38.3). Transmigration was significantly increasedFig. 1. NE activity from activated neutrophils. Effect of DX-890 (10 nM,
100 nM, 1 μM) on NE activity from healthy (A) and CF (B) peripheral blood
neutrophils activated with fMLP. Dotted line represents median spontaneous
NE activity. Data are represented as median± interquartile range of n=5
(normal) and n=6 (CF) experiments. ⁎Wilcoxon signed rank p≤0.05.in response to the chemoattractant fMLP to 47.6% (39.7, 87.1)
(p=0.001). DX-890 pre-treatment of neutrophils significantly
reduced transmigration in response to fMLP to 36.1% (20.9,
53.75) (p=0.02; Fig. 2).
3.3. Nasal epithelial cells
A DX-890 concentration of 500 nM was necessary to inhibit
NE activity in CF sputum sol 1:100. DX-890 did not induce
IL-8 secretion and did not adversely affect cell viability at
doses up to 500 nM (data not shown). Therefore DX-890 was
used at doses up to 500 nM in the epithelial cell study.
Baseline IL-8 secretion was similar between healthy and CF
epithelial cells (median 1.5 μg/ml and 1.3 μg/ml respectively).
NE 50 nM upregulated IL-8 secretion in healthy (2.5 μg/ml)
and CF epithelial cells (2.4 μg/ml). CF sputum sol 1:100 also
upregulated IL-8 secretion in healthy (2.6 μg/ml) and CF epi-
thelial cells (2.0 μg/ml) (Fig. 3).
Pre-incubation with DX-890 (200 nM) reduced NE-induced
IL-8 secretion in healthy (median 2.2 μg/ml) and CF epithelial
cells (median 1.7 μg/ml). Similarly, pre-incubation with
DX-890 (500 nM) was associated with reduced CF sputum
sol-induced median IL-8 secretion in healthy epithelial cells
(1.8 μg/ml) and CF cells (1.7 μg/ml) (Fig. 4).
4. Discussion
Neutrophilic inflammation of the lung is a hallmark of cystic
fibrosis and greatly contributes to the pathogenesis of lung dis-
ease. DX-890 reduces the release of active NE from fMLP-
stimulated neutrophils and reduces migration of neutrophils
through an epithelial monolayer in vitro. DX-890 also reduced
IL-8 release from CF and healthy NEC following stimulation
with NE and CF sol.
NE is essential for the antimicrobial activity of neutrophils,
both in degradation of phagocytosed microbes and those caught
in neutrophil extracellular traps (NETs) [17]. The necessity of
NE in the immune defense against Gram negative bacteria is
demonstrated by the mortality of NE deficient mice [18]. TheFig. 2. Neutrophil transmigration. Effect of DX-890 (500 nM) on transmigra-
tion of neutrophils through an epithelial monolayer in response to fMLP
(100 nM). Neutrophils that transmigrated to the lower chamber are expressed
as a percentage of total neutrophil added to apical chamber. Triplicate values
for n=4 experiments are presented as median and interquartile range.
⁎Wilcoxon signed rank test p≤0.05.
Fig. 3. IL-8 release from epithelial cells in response to NE and CF sputum sol.
IL-8 release from healthy and CF nasal epithelial cells in response to NE 50 nM
and CF sol 1:100. Data are median and interquartile range and are duplicate
values for n=6 experiments. ⁎Wilcoxon signed rank test p≤0.005 compared
to non-treated (normal cells). ΦWilcoxon signed rank test p≤0.005 compared
to non-treated (CF cells).
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of the immune system, over-abundance has degradative and
pro-inflammatory effects in diseases such as cystic fibrosis.
Neutrophilia occurs in the CF lung from infancy [19] and
much of the subsequent lung damage can be attributed to neu-
trophil necrotic products, NE in particular. Reduction of airway
NE levels could break the destructive cycle of airway inflam-
mation and reduce lung damage in CF.
DX-890 is a potent small peptide inhibitor of NE that has
previously been shown to reduce lung injury and neutrophil ac-
cumulation in the lungs of rats [20]. We investigated if DX-890
could modify neutrophil function, specifically NE activityFig. 4. Effect of DX-890 on IL-8 secretion induced by NE and CF sol.
(A) DX-890 (200 nM) reduces IL-8 release induced by NE 50 nM from healthy
and CF nasal epithelial cells. (B) DX-890 (500 nM) reduces IL-8 release indu-
ced by CF sol 1:100 in healthy and CF nasal epithelial cells. Data are presented
as median and interquartile range and are duplicate values for n=6 experiments.
⁎Wilcoxon signed rank test p≤0.05.following fMLP stimulation of the cell. No difference in NE re-
lease was observed between CF and normal neutrophils at base-
line, but following stimulation with fMLP, more NE was
released by normal neutrophils. Brockbank et al. found that
CF blood neutrophils release more spontaneous NE than nor-
mal blood neutrophils, but after stimulation with fMLP more
NE was released from normal neutrophils [21]. Another study
showed that CF and normal neutrophils release similar amounts
of spontaneous NE but CF neutrophils release more NE follow-
ing stimulation with TNF-α and IL-8 [22]. The disparity in the
behavior of neutrophils across these studies may be due to dif-
ferences in isolation and treatment as well as the stimulus used
to provoke degranulation. We demonstrated that DX-890 re-
duced activity of NE released by both healthy and CF blood
neutrophils in response to fMLP.
Another strategy for dampening neutrophilic inflammation
in the airway is to reduce migration of neutrophils from the
bloodstream to the airway. The role, if any, played by neutro-
philic proteases in transmigration is controversial. Several ro-
dent studies have demonstrated that NE inhibitors decrease
neutrophil migration to the airway following stimulation such
as lung injury [20,23–25], although other studies do not sup-
port these findings [26–28].
Rees et al. found that a NE inhibitor protected against rodent
lung injury induced by the instillation of NE or CF sputum sol
[29]. Our results demonstrate that pre-incubation of neutrophils
with DX-890 reduces transmigration through an epithelial cell
monolayer in response to fMLP. Delacourt et al. demonstrated
that DX-890 reduced neutrophil migration through a Matrigel
basement membrane [20]. Following the observation that fol-
lowing mechanical ventilation, NE −/− mice had significantly
less neutrophil infiltration into the lung than wild type, Kaynar
and colleagues demonstrated the necessity of NE for neutrophil
migration across endothelium but not Matrigel [24]. Results
from our model build upon observations from the Delacourt
study and suggests that NE activity is involved in at least two
portions (interstitium and epithelium) of the neutrophils' trans-
migration from blood vessel to airway lumen.
Extracellular NE drives inflammation by stimulating nasal
epithelial cells (NEC) to secrete pro-inflammatory mediators
such as IL-8. This study demonstrates that DX-890 reduced
IL-8 release induced by NE and CF sol from CF and non-CF
NEC. In these experiments, the dose of DX-890 used greatly
exceeded the stimulatory dose of NE and was sufficient to ne-
gate NE activity in samples (data not shown). CF sputum sol
contains many factors capable of stimulating IL-8 secretion
such as other proteases and bacterial components and it is not
therefore surprising that DX-890 only partially reduces IL-8 se-
cretion. It is more difficult to speculate as to why DX-890 did
not completely prevent NE-induced IL-8 secretion. In other
studies that carried out similar experiments using different NE
inhibitors [30–32], NE and the inhibitor were co-incubated be-
fore application to the cells. In this study DX-890 was added to
cells prior to stimulation with NE. This pre-incubation of DX-
890 may have caused inactivation of DX-890 via interaction
with cellular secretions, cell membranes or culture media com-
ponents, reducing the concentration of DX-890 available for
304 F.K. Dunlevy et al. / Journal of Cystic Fibrosis 11 (2012) 300–304subsequent inhibition of NE activity. It is possible that if NE
and DX-890 were pre-incubated prior to stimulation of cells,
the prevention of IL-8 secretion would be greater.
DX-890 has already demonstrated tolerability in rodents
[23] and in a Phase I clinical trial in humans [33]. In conclu-
sion, this study showed that DX-890 inhibits NE activity in
neutrophils and reduces neutrophil transmigration through an
epithelial cell monolayer. DX-890 also dampens secretion of
IL-8 from primary nasal epithelial cells in response to stimula-
tion with NE and CF sputum sol. These data support the further
investigation of DX-890 for the treatment of airway diseases
involving neutrophilic inflammation, such as cystic fibrosis.
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